Page last updated: 2024-08-17

carbostyril and Progeria

carbostyril has been researched along with Progeria in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Avallone, H; Cao, K; Capell, BC; Chen, X; Collins, FS; Conneely, KN; Erdos, MR; Faddah, DA; Ganesh, SK; Kolodgie, FD; Nabel, EG; Olive, M; Qu, X; San, H; Tavarez, UL; Virmani, R1
Bendale, P; Gelb, MH; Huyer, G; Mallampalli, MP; Michaelis, S1

Other Studies

2 other study(ies) available for carbostyril and Progeria

ArticleYear
A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model.
    Proceedings of the National Academy of Sciences of the United States of America, 2008, Oct-14, Volume: 105, Issue:41

    Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Mice; Progeria; Quinolones

2008
Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
    Proceedings of the National Academy of Sciences of the United States of America, 2005, Oct-04, Volume: 102, Issue:40

    Topics: Amino Acid Motifs; Blotting, Western; Cell Nucleus; Fibroblasts; Green Fluorescent Proteins; HeLa Cells; Humans; Lamin Type A; Lipoproteins; Membrane Proteins; Metalloendopeptidases; Metalloproteases; Mutation; Nuclear Proteins; Progeria; Protein Precursors; Protein Prenylation; Quinolones

2005